Mikhail Blagosklonny is among the world leading scientists in the aging and cancer. He is a top oncology professor and has conducted significant research in the field. Blagosklonny currently works at the Roswell Park Cancer Institute. The scientist is an alumnus of the First Pavlov State Medical University of St. Petersburg where he got his Ph.D. in experimental medicine and cardiology and a master’s degree in internal medicine. In 2002, Mikhail was appointed as an associate professor at the New York Medical College. He served the organization for a few years before being hired as a senior scientist at the Ordway Research Institute. In 2009, the professor joined the Roswell Park Cancer Institute, and he has been serving it to date. Blagosklonny has gained a wealth of experience in oncology for the years that he been in the field, and this enables him to be highly useful at the institute. He has currently focused researching areas such as cancer, biogerontology, anti-aging, and various targeted cancer therapies that do not have an adverse effect in healthy cells.
The scientist works at Oncotarget and Cell Cycle as an editor in chief. He has also been acting as an associate editor in therapy and cancer biology. Mikhail has had an opportunity to be part of the researchers who serve on the Cell Death and Differentiation’s editorial board. The professor has developed a hypothesis that focuses on how medical professionals can utilize TOR signaling potential in the treatment of aging and cancer problems. He encourages the use Rapamycin, which is a strong cure for cancer. Mikhail has actively taken part in longevity research. The fields that the professor has dealt with include clinical investigations, molecular biology, and cellular biology. In his career, he has studied about tumor suppressors, drug resistance, ontogenesis, anticancer therapeutics, apoptosis, mitosis, and signal transduction.
Mikhail Blagosklonny has written a lot of the useful content that enlightens people about the aging hyperfunction theory. He has discussed cyclotherapy engineering and cell chemotherapeutic. The professor is globally appreciated due to the research that he has done. He believes that Rapamycin can be used in treating individuals who have cancer. Blagosklonny has currently written more than 300 book chapters, research articles, and reviews. His knowledge has made the International Journal of Cancer, American Journal of Pathology, PLoS ONE, and many other organizations to hire him as an associate editor. He is a hardworking and committed person, and this has enabled him to be among the most successful oncology researchers. Mikhail believes that he values human life, and this inspired him to join the sector so that he could make the world disease free.The useful research work that Blagosklonny does has significantly benefited the Roswell Park Cancer Institute since he joined it in 2009. The organization has been acting as a place where different professionals can come together and share their approaches in how cancer can be cured. Roswell Park Cancer Institute’s scientists are currently working to determine how aging can be prevented by curing cancer. Mikhail’s oncology expertise has been useful to the institute.